Peptide Based Metabolic Disorders Therapeutics Market: Liraglutide Dominates the Drug Class Category
Verfasser: ashwani_kailiya on Friday, 10 May 2019Peptide based drugs have panned out as an essential class of therapeutics owing to exhaustive research conducted at pharmaceutical and biotech companies. In the past decades, tremendous development in synthetic peptide technologies have been witnessed, which has boosted researchers and pharmaceuticals industries to identify peptides of clinical utility and surmount problems demoralizing commercialization. Owing to high biological activity, high membrane penetration ability and low cost, peptides have been preferred over small molecules.
Get Free Sample Report Here: https://www.factmr.com/connectus/sample?flag=S&rep_id=187
Given huge number of therapeutic peptides have been approved and are available, and many are in later stages or are subject of clinical trials, peptides have bolstered its future in medicine. The use of therapeutic peptides to manage diseases such as cardiovascular, metabolic disorders, cancer, nerurodegenerative, and infectious diseases has soared in the recent past.
A considerable amount of research is being done to focus on peptide based inhibitors for disease management. As such, emerging peptide technologies are expected to broaden therapeutic applications.